Table 2.

Effect of Zaltoprofen and Zileuton on oxidative stress markers against MNU induced mammary gland carcinoma.

Groups	TBARS (nM of MDA/mg of protein)	GSH*10−4 (mg %)	SOD (unit of SOD/mg of protein)	Catalase (nM of H2O2/min/mg of protein)	Protein Carbonyl (nM/ml)
Group I Control (Normal Saline, 3 ml/kg, i.p.)	0.088 ± 0.02	0.076 ± 0.00	0.256 ± 0.02	1.66 ± 0.09	55.98 ± 13.06
Group II Toxic Control (MNU 47 mg/kg, i.v.)	0.229 ± 0.07***	0.065 ± 0.00	0.224 ± 0.02	1.51 ± 0.06	78.10 ± 9.04
Group III Zaltoprofen (10 mg/kg, p.o.)	0.150 ± 0.05a	0.061 ± 0.00	0.205 ± 0.01a	1.28 ± 0.01***	72.87 ± 5.47
Group IV Zileuton (10 mg/kg, p.o.)	0.089 ± 0.01a	0.077 ± 0.01	0.305 ± 0.00b	1.53 ± 0.15	66.59 ± 31.52
Group V Zaltoprofen+ Zileuton (5 + 5 mg/kg, p.o.)	0.086 ± 0.00***	0.066 ± 0.00	0.607 ± 0.29***	1.32 ± 0.13***	62.04 ± 3.05

(Values are Mean ± SD), each group contains eight animals. Comparisons were made on the basis of the one-way Anova followed by Bonferroni test. All groups were compared to the MNU treated group (

^***p < 0.001). Group V were compared to the III and IV treated group (

^ap < 0.001,

^bp < 0.01).